Advancing STAT6 And TYK2 Clinical Programs Will Open New Therapeutic Markets

Shared on01 May 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Increased 0.62%

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 333.9x to 376.4x.

Shared on09 Apr 25
Fair value Decreased 1.09%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 25%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.